Published in Mol Cancer Ther on May 01, 2014
Drug repurposing in oncology-patient and health systems opportunities. Nat Rev Clin Oncol (2015) 1.25
A survey of current trends in computational drug repositioning. Brief Bioinform (2015) 1.18
Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research. BMC Med Genomics (2015) 0.90
Leveraging big data to transform target selection and drug discovery. Clin Pharmacol Ther (2016) 0.84
Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia. Mol Syst Biol (2015) 0.76
Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia. Mol Syst Biol (2015) 0.76
Expression Profiling Identifies Bezafibrate as Potential Therapeutic Drug for Lung Adenocarcinoma. J Cancer (2015) 0.75
Repurposing paclitaxel for the treatment of fibrosis: indication discovery for existing drugs. Drug Des Devel Ther (2015) 0.75
Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets. Nat Commun (2017) 0.75
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med (2011) 5.30
Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc (2006) 4.43
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer (2010) 3.78
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res (2005) 3.00
Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res (2005) 2.67
Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res (2009) 2.63
Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol (2012) 2.58
Zeb1 links epithelial-mesenchymal transition and cellular senescence. Development (2008) 2.55
Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol (1998) 2.49
Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci U S A (2008) 2.27
Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A (2001) 2.22
Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol (2005) 2.05
Partial resolution of the enzymes catalyzing oxidative phosphorylation. 8. Properties of a factor conferring oligomycin sensitivity on mitochondrial adenosine triphosphatase. J Biol Chem (1966) 1.95
Novel immunotherapeutic strategies in development for renal cell carcinoma. Eur Urol (2012) 1.60
mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer (2008) 1.37
Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med (2001) 1.29
Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res (2011) 1.12
Oligomycin-induced bioenergetic adaptation in cancer cells with heterogeneous bioenergetic organization. J Biol Chem (2010) 1.11
Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma. Chemotherapy (2013) 1.10
Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol (2004) 1.08
Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther (2002) 1.03
Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers. Stem Cells (2012) 1.03
Use of levodopa to relieve pain from painful symmetrical diabetic polyneuropathy. Pain (1998) 1.03
A novel pathway involving melanoma differentiation associated gene-7/interleukin-24 mediates nonsteroidal anti-inflammatory drug-induced apoptosis and growth arrest of cancer cells. Cancer Res (2006) 1.02
Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells. Eur J Pharmacol (2006) 0.96
Impact of an altered Wnt1/β-catenin expression on clinicopathology and prognosis in clear cell renal cell carcinoma. Int J Mol Sci (2013) 0.94
The tricyclic antidepressant amitriptyline inhibits D-cyclin transactivation and induces myeloma cell apoptosis by inhibiting histone deacetylases: in vitro and in silico evidence. Mol Pharmacol (2011) 0.92
Inositol 1,4,5-trisphosphate 3-kinase-A is a new cell motility-promoting protein that increases the metastatic potential of tumor cells by two functional activities. J Biol Chem (2009) 0.90
Effects of yohimbine on cerebral blood flow, symptoms, and physiological functions in humans. Psychosom Med (2000) 0.89
Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol (2009) 0.89
Genetic dissection of drug resistance in trypanosomes. Parasitology (2013) 0.86
Drug safety evaluation of exemestane. Expert Opin Drug Saf (2011) 0.83
Potent and selective inhibition of hepatitis C virus replication by novel phenanthridinone derivatives. Biochem Biophys Res Commun (2011) 0.83
Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common chemotherapeutic drugs. Anticancer Drugs (2010) 0.83
Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer. J Urol (2007) 0.82
Pentamidine sensitizes chronic myelogenous leukemia K562 cells to TRAIL-induced apoptosis. Leuk Res (2012) 0.81
The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer. Mol Cancer Ther (2004) 0.80
Pentamidine reduces expression of hypoxia-inducible factor-1α in DU145 and MDA-MB-231 cancer cells. Cancer Lett (2011) 0.78
Theoretical and vibrational studies of 4,5-diphenyl-2-2 oxazole propionic acid (oxaprozin). Spectrochim Acta A Mol Biomol Spectrosc (2010) 0.77
Opposite effects of low oligomycin concentrations on the apoptosis of normal and tumor cells. Dokl Biol Sci (2003) 0.76